Literature DB >> 15564483

Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.

Florian Kühnel1, Bernd Schulte, Thomas Wirth, Norman Woller, Sonja Schäfers, Lars Zender, Michael Manns, Stefan Kubicka.   

Abstract

Expression of cellular receptors determines viral tropism and limits gene delivery by viral vectors. Protein transduction domains (PTDs) have been shown to deliver proteins, antisense oligonucleotides, liposomes, or plasmid DNA into cells. In our study, we investigated the role of several PTD motifs in adenoviral infection. When physiologically expressed, a PTD from human immunodeficiency virus transactivator of transcription (Tat) did not improve adenoviral infection. We therefore fused PTDs to the ectodomain of the coxsackievirus-adenovirus receptor (CAR(ex)) to attach PTDs to adenoviral fiber knobs. CAR(ex)-Tat and CAR(ex)-VP22 allowed efficient adenoviral infection in nonpermissive cells and significantly improved viral uptake rates in permissive cells. Dose-dependent competition of CAR(ex)-PTD-mediated infection using CAR(ex) and inhibition experiments with heparin showed that binding of CAR(ex)-PTD to both adenoviral fiber and cellular glycosaminoglycans is essential for the improvement of infection. CAR(ex)-PTD-treated adenoviruses retained their properties after density gradient ultracentrifugation, indicating stable binding of CAR(ex)-PTD to adenoviral particles. Consequently, the mechanism of CAR(ex)-PTD-mediated infection involves coating of the viral fiber knobs by CAR(ex)-PTD, rather than placement of CAR(ex) domains on cell surfaces. Expression of CAR(ex)-PTDs led to enhanced lysis of permissive and nonpermissive tumor cells by replicating adenoviruses, indicating that CAR(ex)-PTDs are valuable tools to improve the efficacy of oncolytic therapy. Together, our study shows that CAR(ex)-PTDs facilitate gene transfer in nonpermissive cells and improve viral uptake at reduced titers and infection times. The data suggest that PTDs fused to virus binding receptors may be a valuable tool to overcome natural tropism of vectors and could be of great interest for gene therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564483      PMCID: PMC533898          DOI: 10.1128/JVI.78.24.13743-13754.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.

Authors:  J Wesche; S Olsnes
Journal:  Biochemistry       Date:  2001-04-10       Impact factor: 3.162

2.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.

Authors:  Y Y Wan; R P Leon; R Marks; C M Cham; J Schaack; T F Gajewski; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors.

Authors:  Lars Zender; Reiner Köck; Matthias Eckhard; Bernd Frericks; Thomas Gösling; Thomas Gebhardt; Susanne Drobek; Michael Galanski; Florian Kühnel; Michael Manns; Stefan Kubicka
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

5.  Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape.

Authors:  Robert W Walters; Paul Freimuth; Thomas O Moninger; Ingrid Ganske; Joseph Zabner; Michael J Welsh
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

6.  Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells.

Authors:  I Dmitriev; E Kashentseva; B E Rogers; V Krasnykh; D T Curiel
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.

Authors:  P A Wender; D J Mitchell; K Pattabiraman; E T Pelkey; L Steinman; J B Rothbard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.

Authors:  H Fechner; X Wang; H Wang; A Jansen; M Pauschinger; H Scherübl; J M Bergelson; H P Schultheiss; W Poller
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

9.  Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes.

Authors:  M R Schmidt; B Piekos; M S Cabatingan; R T Woodland
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

10.  Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection.

Authors:  George Miller; Svenja Lahrs; Venu G Pillarisetty; Alaap B Shah; Ronald P DeMatteo
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

View more
  6 in total

1.  Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.

Authors:  Engin Gürlevik; Norman Woller; Nina Strüver; Peter Schache; Arnold Kloos; Michael P Manns; Lars Zender; Florian Kühnel; Stefan Kubicka
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

Review 2.  Noncovalently associated cell-penetrating peptides for gene delivery applications.

Authors:  Nabil A Alhakamy; Adane S Nigatu; Cory J Berkland; Joshua D Ramsey
Journal:  Ther Deliv       Date:  2013-06

3.  Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors.

Authors:  Xi Xia; Teng Ji; Pingbo Chen; Xiao Li; Yong Fang; Qinglei Gao; Shujie Liao; Lanying You; Hongbin Xu; Quanfu Ma; Peng Wu; Wencheng Hu; Mingfu Wu; Li Cao; Kezhen Li; Yanjie Weng; Zhiqiang Han; Junchen Wei; Ronghua Liu; Shixuan Wang; Gang Xu; Daowen Wang; Jianfeng Zhou; Ding Ma
Journal:  Mol Cancer       Date:  2011-11-03       Impact factor: 27.401

4.  Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.

Authors:  Tie Han; Yizhe Tang; Hideyo Ugai; Leslie E Perry; Gene P Siegal; Juan L Contreras; Hongju Wu
Journal:  Virol J       Date:  2007-10-24       Impact factor: 4.099

Review 5.  The Utilization of Cell-Penetrating Peptides in the Intracellular Delivery of Viral Nanoparticles.

Authors:  Jana Váňová; Alžběta Hejtmánková; Marie Hubálek Kalbáčová; Hana Španielová
Journal:  Materials (Basel)       Date:  2019-08-22       Impact factor: 3.623

6.  p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication.

Authors:  Engin Gürlevik; Norman Woller; Peter Schache; Nisar P Malek; Thomas C Wirth; Lars Zender; Michael P Manns; Stefan Kubicka; Florian Kühnel
Journal:  Nucleic Acids Res       Date:  2009-05-14       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.